Topics

Inscopix Showcases New Products and Key Scientific Presentations at the 49th Annual Meeting of the Society for Neuroscience

08:00 EDT 3 Oct 2019 | Businesswire

Inscopix researchers to deliver oral presentation describing first use of technology in rhesus macaque

Product launches include innovative software, streamlined workflow solutions and expanded applications for animal models

Inscopix announced today that the company’s miniature microscope-based brain mapping platform was used to empower at least 60 presentations at the 49th annual meeting of the Society for Neuroscience (SfN), held October 19-23 in Chicago. The company will also unveil product updates at Inscopix’s booth #507.

“We are honored to have played a role in enabling 60 scientific presentations this year at SfN, a new milestone since our commercial launch at the 2012 SfN meeting in New Orleans,” said Kunal Ghosh, Ph.D., founder and CEO of Inscopix. “While most of these presentations are based on rodent models, we will introduce our first study in the rhesus macaque, expanding our platform to non-human primates. We will also launch new software and workflow products that unlock the increasing functionality and efficiency of our brain-mapping platform. These innovations will allow brain researchers across the spectrum to catalyze new breakthroughs with speed and scientific rigor.”

Innovative New Products for Brain Mapping

Inscopix will introduce innovative new products at SfN which offer groundbreaking features, greatly streamline the workflow, expand applications for diverse animal models and facilitate integration with other brain mapping modalities. Innovative new software features will enable researchers to map neuronal activity in multiple planes simultaneously, thereby dramatically increasing the number of cells that can be imaged in a brain structure. Other software innovations include data compression to greatly decrease time of transfer, which enables labs to efficiently increase the scale of their studies and streamline projects.

To streamline the workflow, Inscopix is launching an expanded portfolio of its Proview™ Express Probes and Proview™ Integrated Lenses to remove workflow steps and significantly reduce the time to imaging. Expansion of animal model solutions include new Ready-to-Image Viruses for rat and new protocols for marmoset, a non-human primate model. Data will also be presented highlighting co-registration of confocal imaging with Inscopix technology for two-color imaging in freely behaving animals.

Inscopix Presentations

Four abstracts will be presented by Inscopix scientists, including one oral presentation describing the use of its nVoke product to observe deep layers of premotor cortex activity during naturalistic motor behavior in rhesus macaques. Inscopix will provide details of additional abstracts throughout the annual meeting via its corporate Twitter account (@Inscopix).

Presentations by Inscopix:

  • Head mounted microendoscopic calcium imaging in deep layer premotor cortex of behaving rhesus macaque
    Presented by Jonathan Nassi, Ph.D.
    Session 547: New Technologies for Imaging Neuronal Structure and Activity, Room S106
    October 22, 2019 from 2:00 to 2:15 p.m. CDT
  • Large-scale cellular-resolution calcium imaging in 4D during free behavior
    Presented by Kevin Zitelli
    Session 612: Optic Methods: Development and Applications, Hall A
    October 22, 2019 from 2:00 to 3:00 p.m. CDT
  • A validated GCaMP viral method for microendoscopic imaging in rat hippocampus CA1 during active behavior
    Presented by Srishti Gulati
    Session 703: Optical Methods: Applications, Hall A
    October 23, 2019 from 10:00 to 11:00 p.m. CDT
  • Registration across in vivo neuronal imaging modalities: Miniature microscopes to high resolution microscopy
    Presented by Pei Sabrina Xu, Ph.D.
    Session 612: Optic Methods: Development and Applications, Hall A
    October 22, 2019 from 2:00 to 3:00 p.m. CDT

Meeting attendees can visit Inscopix booth #507, or email sales@inscopix.com to schedule an overview with a member of the company.

About nVoke

nVoke is Inscopix’s state-of-the-art miniature microscope-based solution for simultaneous imaging and manipulation of large-scale neural circuit dynamics in freely behaving subjects. With nVoke, researchers at leading research institutions worldwide are pushing the frontiers of neuroscience and asking entirely new questions about how neural circuits shape cognition and behavior in health and disease. For more information, please visit: https://www.inscopix.com/nVoke.

About Inscopix, Inc.

Inscopix empowers the development of next-generation therapeutics for difficult-to-treat brain disorders by enabling innovative research and predictive preclinical therapeutic development. Driven by a North Star of overcoming historic challenges in the field, Inscopix provides validated solutions for real-time mapping of neural activity in brain circuits. These objective, quantitative and in-brain assays are catalyzing unprecedented insights into disease mechanisms and have been shown to be more accurate at predicting clinical efficacy than animal behavior when testing a therapeutic candidate’s capacity to bring the brain back to a normal state. Inscopix’s partner and customer discoveries help decode the brain, inform deeper understanding of mechanisms of action and enable the screening of drugs based on efficacy. For more information, please visit http://www.inscopix.com.

Inscopix Media Contact
Ian Stone
Senior Vice President, Canale Communications
(619) 518-3518
ian@canalecomm.com

NEXT ARTICLE

More From BioPortfolio on "Inscopix Showcases New Products and Key Scientific Presentations at the 49th Annual Meeting of the Society for Neuroscience"

Quick Search

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...